<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02339090</url>
  </required_header>
  <id_info>
    <org_study_id>14VR4</org_study_id>
    <nct_id>NCT02339090</nct_id>
  </id_info>
  <brief_title>Versartis Long-Acting Growth Hormone in Children Compared to Daily rhGH</brief_title>
  <acronym>VELOCITY</acronym>
  <official_title>Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children With Growth Hormone Deficiency.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versartis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versartis Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will compare a twice-monthly somavaratan dosing regimen for non-inferiority of
      treatment effect against daily injections of rhGH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a pivotal study to compare the safety and efficacy of a selected
      dose regimen of somavaratan to daily rhGH. The study is a randomized, multi-center, open
      label study of 12 months duration. The primary endpoint is height velocity at 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2015</start_date>
  <completion_date type="Actual">August 23, 2017</completion_date>
  <primary_completion_date type="Actual">August 23, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (Annual height velocity)</measure>
    <time_frame>12 months</time_frame>
    <description>Annual height velocity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (IGF-I and IGFBP-3 responses to study drug administration)</measure>
    <time_frame>12 months</time_frame>
    <description>IGF-I and IGFBP-3 responses to study drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by he number of patients with adverse events, concomitant medications, safety labs, vital signs, physical exams, and repeat dose immunogenicity.</measure>
    <time_frame>12 Months</time_frame>
    <description>Safety observations will include the number of patients with adverse events, concomitant medications, safety labs, vital signs, physical exams, and repeat dose immunogenicity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Growth Disorders</condition>
  <arm_group>
    <arm_group_label>somavaratan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily rhGH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily recombinant growth hormone therapy administered subcutaneously every day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somavaratan</intervention_name>
    <description>long acting growth hormone therapy</description>
    <arm_group_label>somavaratan</arm_group_label>
    <other_name>Long acting recombinant human growth hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daily rhGH</intervention_name>
    <description>daily growth hormone therapy</description>
    <arm_group_label>Daily rhGH</arm_group_label>
    <other_name>daily growth hormone</other_name>
    <other_name>recombinant growth hormone therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronological Age ≥ 3.0 years and ≤ 10.0 (girls) and ≤ 11.0 (boys).

          -  Pre-pubertal status: Absent breast development in girls, testicular volume &lt; 4.0 mL in
             boys.

          -  Diagnosis of GHD as documented by two or more GH stimulation test results ≤ 10.0
             ng/mL.

          -  Height SD score ≤ -2.0 at screening.

          -  Weight for Stature ≥ 10th percentile.

          -  IGF-I SD score ≤ -1.0 at screening.

          -  Delayed bone age (≥ 6 months).

        Exclusion Criteria:

          -  Prior treatment with any growth promoting agent

          -  History of or concurrent significant disease (e.g. diabetes, cystic fibrosis, renal
             insufficiency).

          -  Chromosomal aneuploidy, significant gene mutations (other than those that cause GHD)
             or confirmed diagnosis of a named syndrome.

          -  A diagnosis of Attention Deficit Hyperactivity Disorder.

          -  Daily use of anti-inflammatory doses of glucocorticoid.

          -  Prior history of leukemia, lymphoma, sarcoma or cancer.

          -  Treatment with an investigational drug in the 30 days prior to screening.

          -  Known allergy to constituents of the study drug formulation.

          -  Ocular findings suggestive of increased intracranial pressure and/or retinopathy at
             screening.

          -  Significant spinal abnormalities including scoliosis, kyphosis and spina bifida
             variants.

          -  Significant abnormality in screening laboratory studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Will Charlton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2015</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VRS-317</keyword>
  <keyword>Growth Hormone Deficiency</keyword>
  <keyword>Long Acting Recombinant Growth Hormone</keyword>
  <keyword>Long Acting Growth Hormone</keyword>
  <keyword>Pediatric Growth Hormone Deficiency</keyword>
  <keyword>Growth Hormone Replacement Therapy</keyword>
  <keyword>Versartis</keyword>
  <keyword>Xten</keyword>
  <keyword>Human Growth Hormone</keyword>
  <keyword>somavaratan</keyword>
  <keyword>growth failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Growth Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

